Oligodeoxyribonucleotides

03/01/2008 - "Here, we report that treatment with an antisense oligodeoxynucleotide against this chimeric gene was very useful for inducing the regression of ES tumor growth; thus, this chimeric gene may be an important target for the treatment of ES patients."
10/01/2009 - "Until now, the anti-tumor efficacy of synthetic oligodeoxynucleotides containing CpG motifs (CpG ODNs) has been reported in a number of preventive and therapeutic tumor models. "
04/05/2013 - "Locally injected immunostimulatory oligodeoxynucleotides containing CpG motifs (CpG-ODNs), which are TLR9 agonists, have shown promise in cancer models. "
08/15/2007 - "Although the efficacy of CpG oligodeoxynucleotides has been thought to depend on the expression of TLR9, we unexpectedly found that tumor rejection did not require host expression of TLR9. "
09/09/2004 - "An immune modulator, such as CpG oligodeoxynucleotides which promote Th1-type immune responses was combined to increase the efficacy of tumor recognition and elimination. "

02/15/2007 - "Mucosal delivery of CpG oligodeoxynucleotide (ODN) in mice has been shown to induce potent innate immunostimulatory responses and protection against infection. "
01/15/2016 - "We discovered that treating mice with an A-class CpG-oligodeoxynucleotide (ODN) at 2 h after traumatic injury significantly improved mouse survival following early-onset secondary lung infection with S. "
08/15/2011 - "Intranasal delivery of CpG oligodeoxynucleotides also provided significant protection; however, combining preexposure vaccination with CpG treatment at the time of infection or up to 18 hours after infection, provided significantly greater protection than either treatment alone. "
06/30/2010 - "To study the protective effects on the infection of Schistosoma japonicum in C57BL/6 mice induced by dendritic cells DCs pulsed with GST in combination with CpG oligodeoxynucleotide. "
09/13/2005 - "Treatment with synthetic oligodeoxynucleotides containing CpG motifs (CpG ODNs) is remarkably protective against otherwise lethal infection. "

01/01/2018 - "Suppressive oligodeoxynucleotides (ODN) containing repetitive TTAGGG motifs present in mammalian telomeres have proven useful in the treatment of autoimmune diseases including SLE. "
04/01/2005 - "Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?"
07/01/2007 - "The inhibition of immune responses by regulatory oligodeoxynucleotides may be useful for the treatment of immune-mediated disorders including autoimmune diseases and graft rejection."
01/01/2023 - "More importantly, inhibitory oligodeoxynucleotides have been used to treat immune-mediated inflammatory diseases, including inflammatory disorders and autoimmune diseases. "
12/01/2014 - "Suppressive oligodeoxynucleotides (Sup ODN) express repetitive TTAGGG motifs that have proven useful in the treatment/prevention of numerous inflammatory and autoimmune diseases. "

11/01/2007 - "We investigated the therapeutic efficacy of in vivo DC activation, by directly administering glioma cell lysate with CpG oligodeoxynucleotides (CpG/lysate), in glioma-bearing mice. "
01/01/2016 - "These results revealed a promising treatment of glioma by oligodeoxynucleotide aptamer."
08/01/2007 - "c-Met antisense oligodeoxynucleotides as a novel therapeutic agent for glioma: in vitro and in vivo studies of uptake, effects, and toxicity."
08/01/2007 - "These data are encouraging for further study of c-Met antisense oligodeoxynucleotides as a therapeutic modality for glioma."
01/01/2000 - "Studies on uptake, sub-cellular trafficking and efflux of antisense oligodeoxynucleotides in glioma cells using self-assembling cationic lipoplexes as delivery systems."

10/01/2018 - "Treatment with miR-223Y/--derived neutrophils, or miR-223 antisense oligodeoxynucleotides in S. aureus-infected wild-type wounds markedly improved the healing of these otherwise chronic, slow healing wounds. "
09/25/1995 - "However, such treatment significantly decreased mortality and improved behavioral recovery at 2 weeks after trauma as compared to animals treated with the corresponding sense oligodeoxynucleotides. "
09/01/2014 - "Similarly, transient knockdown of Foxo1 at the wound site by local delivery of antisense oligodeoxynucleotides enhanced skin wound healing. "
12/01/2010 - "COL1A1 oligodeoxynucleotides decoy: biochemical and morphologic effects in an acute wound repair model."
09/25/1995 - "Administration of antisense oligodeoxynucleotides (15 nmol/ml twice daily x 2 days) did not alter physiological variables or motor function prior to trauma. "